A phase Ib study of everolimus combined with metformin for patients with advanced cancer
Conclusion The combination of everolimus and metformin is poorly tolerated in patients with advanced cancer. The pharmacokinetic interaction between everolimus and metformin may have implications for diabetic cancer patients that are treated with these drugs. Our results advocate for future clinical trials with combinations of other mTOR inhibitors and biguanides.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Diabetes | Drugs & Pharmacology | Endocrinology | Fortamet | Investigational New Drugs | Metformin | Study | Toxicology